FredrickB.HagemeisterMD

PubMed

• Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.
  Ashwath Gurumurthi, Collin K Chin, Lei Feng, Nathan H Fowler, Paolo Strati
  Eclinicalmedicine. 2024-08-01
• Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 s...
  Max J Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B Hagemeister
  Cancer. 2024-03-15
• 5 citations
  Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
  Zijun Y Xu-Monette, Yong Li, Thomas Snyder, Tiantian Yu, Tingxun Lu
  Clinical Cancer Research. 2023-12-01

Journal Articles

• Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma  
  Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology

Abstracts/Posters

• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  F. B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Fredrick B. Hagemeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia 2012 
  CancerNet, LLC, Irving, Texas - 5/12/2012
• 5th Symposium on Emerging Treatments & Advances in Novel Cancer Therapies for Practicing Physicians & Healthcare Professionals 
  CancerNet, LLC, Dallas, Texas - 1/18/2012
• Join now to see all